India, Aug. 19 -- Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals, has announced the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (single-dose vial). The product is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine® (Astellas Pharma US, Inc., NDA – 021506). Distribution is expected to begin in September 2025.
According to IQVIA sales data for the 12 months ending June 2025, the Mycamine® for Injection market (50 mg/vial and 100 mg/vial, including all available therapeutic equivalents) recorded annual sales of approximately USD 60.7 million.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America at Glenmark, said:
"W...